BMC Gastroenterology | |
Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival | |
Research Article | |
Adamantia Zizi-Serbetzoglou1  Ioannis Koutsounas2  Stamatios Theocharis2  Nicolaos Tsoukalas2  Efstratios Patsouris2  Constantinos Giaginis3  Christos Damaskos4  Gregorios Kouraklis4  | |
[1] Department of Pathology, Tzaneio General Hospital, Piraeus, Greece;First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece;First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece;Department of Food Science and Nutrition, School of Environment, University of the Aegean, Mitropoliti Ioakeim 2, 81400, Myrina, Limnos, Greece;Second Department of Propedeutic Surgery, Medical School, University of Athens, Athens, Greece; | |
关键词: Histone deacetylase; Pancreatic adenocarcinoma; Immunohistochemistry; Clinicopathological parameters; Patients’ survival; | |
DOI : 10.1186/s12876-015-0379-y | |
received in 2015-07-01, accepted in 2015-10-15, 发布年份 2015 | |
来源: Springer | |
【 摘 要 】
BackgroundHistone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 and −6 protein expression in pancreatic adenocarcinoma.MethodsHDAC-1, −2, −4 and −6 protein expression was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and patients’ survival.ResultsEnhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity (p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4 expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and −6 expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634).ConclusionsThe present study suggested that HDACs may be implicated in pancreatic malignant disease progression, being considered of clinical utility with potential use as therapeutic targets.
【 授权许可】
CC BY
© Giaginis et al. 2015
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311101090309ZK.pdf | 987KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]